2025
Diabetes Status and Long-Term Mortality and Major Amputation Outcomes Following Revascularization in Chronic Limb Threatening Ischemia
Callegari S, Romain G, Aggarwal A, Cleman J, Smolderen K, Mena-Hurtado C. Diabetes Status and Long-Term Mortality and Major Amputation Outcomes Following Revascularization in Chronic Limb Threatening Ischemia. Journal Of Vascular Surgery 2025 PMID: 40348290, DOI: 10.1016/j.jvs.2025.04.065.Peer-Reviewed Original ResearchChronic limb-threatening ischemiaLower-extremity bypassSub-hazard ratiosPeripheral vascular interventionsDM statusRisk of deathLimb-threatening ischemiaTeam-based careShared decision-makingCumulative incidenceDiabetes mellitusMedicare claims dataCumulative incidence of mortalityAll-cause mortalityType of revascularizationAmputation outcomesCare offerFine-Gray modelClaims dataCumulative incidence of deathLong-term mortalityMortality riskCox regression modelsHazard ratioDiabetes statusUsing Radiology as a Screening Tool to Identify Intimate Partner Violence
Lenehan P, Tang A, Watane G, Gujrathi R, Park H, Gosangi B, Thomas R, Franco F, Patel K, Warsofsky I, Rosner B, Khurana B. Using Radiology as a Screening Tool to Identify Intimate Partner Violence. Journal Of The American College Of Radiology 2025, 22: 395-404. PMID: 40044319, PMCID: PMC11887577, DOI: 10.1016/j.jacr.2025.01.003.Peer-Reviewed Original ResearchConceptsAdjusted incidence rate ratiosEmergency departmentRetrospective case-control studyImaging utilization patternsEvident injuriesCox proportional hazards regressionRace-matched controlsCase-control studyTime-to-event analysisProportional hazards regressionImaging utilizationIncidence rate ratiosCumulative incidenceAnatomical sitesScreening mammogramsHazards regressionOdds ratioImaging studiesIntimate partner violencePatientsInjury patternsLogistic regressionInjuryOrgan systemsPoisson regressionSeverity and Long-Term Mortality of COVID-19, Influenza, and Respiratory Syncytial Virus
Bajema K, Bui D, Yan L, Li Y, Rajeevan N, Vergun R, Berry K, Huang Y, Lin H, Aslan M, Ioannou G. Severity and Long-Term Mortality of COVID-19, Influenza, and Respiratory Syncytial Virus. JAMA Internal Medicine 2025, 185: 324-334. PMID: 39869355, PMCID: PMC11773409, DOI: 10.1001/jamainternmed.2024.7452.Peer-Reviewed Original ResearchConceptsRespiratory syncytial virusLong-term mortalitySARS-CoV-2Syncytial virusCohort studyAssociated with higher long-term mortalityRisk differenceIntensive care unit admissionSeasonal influenza vaccineRetrospective cohort studyDisease severity of COVID-19Long-term deathAssociated with more severe disease outcomesRisk of deathCompare disease severitySevere disease outcomesRisk of hospitalizationSeverity of COVID-19Same-day testingInfluenza vaccineInverse probability weightingUnit admissionCumulative incidenceMortality of COVID-19Primary outcomeClinical outcomes and care for spontaneous bacterial peritonitis: A national cohort study.
Serper M, Tang H, Zhang S, McCullough A, Kaplan D, Taddei T, Mahmud N. Clinical outcomes and care for spontaneous bacterial peritonitis: A national cohort study. Hepatology 2025 PMID: 39879583, DOI: 10.1097/hep.0000000000001251.Peer-Reviewed Original ResearchIn-hospital mortalityImprove care outcomesPopulation-based studyNational cohort studyQuality measuresHazard of mortalityPost-discharge mortalityNational cohort of patientsCare outcomesSpontaneous bacterial peritonitisInformal careHealth systemPatient clinical factorsAcute kidney injuryBundle componentsRecurrent spontaneous bacterial peritonitisNational cohortCohort studyIncidence of stage 3In-hospitalClinical factorsStage 3Cohort of patientsCumulative incidenceBacterial peritonitis
2024
Chiropractic Spinal Manipulation and Fall Risk in Older Adults With Spinal Pain: Observational Findings From a Matched Retrospective Cohort Study
Trager R, Burton W, Loewenthal J, Perez J, Lisi A, Kowalski M, Wayne P. Chiropractic Spinal Manipulation and Fall Risk in Older Adults With Spinal Pain: Observational Findings From a Matched Retrospective Cohort Study. Cureus 2024, 16: e72330. PMID: 39583476, PMCID: PMC11585376, DOI: 10.7759/cureus.72330.Peer-Reviewed Original ResearchSpinal manipulative therapyNegative control outcomesSpinal painFall riskRisk ratioOlder adultsLimb fracturesChiropractic spinal manipulative therapyCumulative incidence of fallsChiropractic spinal manipulationFall risk factorsReducing fall riskIncidence of fallsAssociated with fallsControl outcomesRandomized controlled trialsSpinal manipulationManipulative therapyInjurious fallsCumulative incidenceCare utilizationRetrospective cohort studyFracture incidenceCohort studyControlled trialsLenalidomide in Transfusion-Dependent IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes and Isolated Del(5q): Results of a European Postauthorization Safety Surveillance Study
Poloni A, Raaschou-Jensen K, Mohedo F, Paolini S, Oliva E, Buccisano F, Vasconcelos A, Kim I, Makwana A, Bernasconi D, Rosettani B, Prebet T, Santini V. Lenalidomide in Transfusion-Dependent IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes and Isolated Del(5q): Results of a European Postauthorization Safety Surveillance Study. Clinical Lymphoma Myeloma & Leukemia 2024, 25: e131-e142. PMID: 39516085, DOI: 10.1016/j.clml.2024.10.007.Peer-Reviewed Original ResearchInternational Prognostic Scoring SystemDose of lenalidomideMyelodysplastic syndromeIsolated del(5qAcute myeloid leukemiaBenefit-risk profileSafety populationTransfusion-dependentOverall survivalCumulative incidenceCumulative incidence of acute myeloid leukemiaGrade 3/4 treatment-emergent adverse eventsNon-interventional post-authorization safety studyInternational Prognostic Scoring System low-Intermediate-1-risk myelodysplastic syndromeIncidence of acute myeloid leukemiaLower-risk myelodysplastic syndromesTreatment-emergent adverse eventsEffects of lenalidomidePrognostic Scoring SystemKaplan-Meier analysisPost-authorization safety studyRoutine careClinical trial dataSafety surveillance studyRisk of bleeding in patients with essential thrombocythemia and extreme thrombocytosis
Venkat R, Redd R, Harris A, Aryee M, Marneth A, Kamaz B, Kim C, Wazir M, Weeks L, Stahl M, DeAngelo D, Lindsley R, Luskin M, Hobbs G, How J. Risk of bleeding in patients with essential thrombocythemia and extreme thrombocytosis. Blood Advances 2024, 8: 6043-6054. PMID: 39293089, PMCID: PMC11635702, DOI: 10.1182/bloodadvances.2024013777.Peer-Reviewed Original ResearchConceptsRisk of bleedingClinically relevant nonmajor bleedingEssential thrombocythemiaBleeding riskPlatelet countCumulative incidenceDana-Farber Cancer Institute and Massachusetts General HospitalAssociated with acquired von Willebrand syndromeCumulative incidence of thrombosisCumulative incidence of bleedingIncreased bleeding riskIncidence of bleedingReduced bleeding riskVon Willebrand syndromeIncidence of thrombosisNonmajor bleedingDNMT3A mutationsMassachusetts General HospitalThrombotic eventsDana-FarberDiabetes mellitusBleedingPatientsRisk factorsTreatment decisionsInterventional antibiotic treatment replacing antibiotic prophylaxis during allogeneic hematopoietic stem cell transplantation is safe and leads to a reduction of antibiotic administration
Toenges R, Lang F, Ghaffar R, Lindner S, Schlipfenbacher V, Riemann J, Ajib S, Kouidri K, Cremer A, Weber B, Nguyen N, Knoch A, Vehreschild J, Serve H, Bug G. Interventional antibiotic treatment replacing antibiotic prophylaxis during allogeneic hematopoietic stem cell transplantation is safe and leads to a reduction of antibiotic administration. Annals Of Hematology 2024, 103: 4687-4699. PMID: 39237814, DOI: 10.1007/s00277-024-05986-4.Peer-Reviewed Original ResearchGraft-versus-host diseaseSystemic antibiotic prophylaxisNon-relapse mortalityChronic graft-versus-host diseaseAllogeneic hematopoietic stem cell transplantationHematopoietic stem cell transplantationStem cell transplantationClostridium difficile infectionAntibiotic prophylaxisOverall survivalCumulative incidenceBloodstream infectionsCell transplantationAntibiotic treatmentCumulative incidence of acute GVHD grades II-IVSevere chronic graft-versus-host diseaseRisk of graft-versus-host diseaseAcute GVHD grade II-IVGVHD grade II-IVDuration of antibiotic therapyRisk of infection-related mortalityPre-engraftment periodGrade II-IVMedian follow-upInfection-related mortalityMechanical versus Biological Mitral Valve Replacement: Insights from Propensity Score Matching on Survival and Reoperation Rates
Feirer N, Buchner A, Weber M, Lang M, Dzilic E, Amabile A, Geirsson A, Trenkwalder T, Krane M, Vitanova K. Mechanical versus Biological Mitral Valve Replacement: Insights from Propensity Score Matching on Survival and Reoperation Rates. Journal Of Thoracic And Cardiovascular Surgery 2024 PMID: 39067811, DOI: 10.1016/j.jtcvs.2024.07.038.Peer-Reviewed Original ResearchMitral valve replacementBiological mitral valve replacementPropensity-score matchingValve replacementReoperation rateCumulative incidenceFollow-upMechanical mitral valve replacementMedian follow-up timeCumulative incidence of reoperationSurgical mitral valve replacementSymptomatic mitral valve diseaseIncidence of reoperationThirty-day mortalityHigh-volume centersMitral valve diseaseHistory of neurological disordersPropensity score matchingAnalyzed time pointsConcomitant proceduresPeriprocedural complicationsSingle-centerThirty-dayRetrospective studyReoperationRisk prediction for clonal cytopenia: multicenter real-world evidence
Xie Z, Komrokji R, Al Ali N, Regelson A, Geyer S, Patel A, Saygin C, Zeidan A, Bewersdorf J, Mendez L, Kishtagari A, Zeidner J, Coombs C, Madanat Y, Chung S, Badar T, Foran J, Desai P, Tsai C, Griffiths E, Al Malki M, Amanam I, Lai C, Deeg H, Ades L, Arana Yi C, Osman A, Dinner S, Abaza Y, Taylor J, Chandhok N, Soong D, Brunner A, Carraway H, Singh A, Elena C, Ferrari J, Gallì A, Pozzi S, Padron E, Patnaik M, Malcovati L, Savona M, Al-Kali A. Risk prediction for clonal cytopenia: multicenter real-world evidence. Blood 2024, 144: 2033-2044. PMID: 38996210, PMCID: PMC11561536, DOI: 10.1182/blood.2024024756.Peer-Reviewed Original ResearchMyeloid neoplasmsIncidence of MNClonal cytopeniaCumulative incidencePlatelet count <High-risk mutationsCox proportional hazards modelsVariant allele fractionProportional hazards modelClinical trial designCCUS patientsStratify patientsGray's testC-indexDisease entityRisk groupsCytopeniasAllele fractionSomatic mutationsRisk factorsHigh riskNatural historyRisk scoreHazards modelPatientsOutcomes of patients with alcohol‐associated hepatitis and acute kidney injury – Results from the HRS Harmony Consortium
T. A, Allegretti A, Cullaro G, Ouyang T, Asrani S, Chung R, Przybyszewski E, Wilechansky R, Robinson J, Sharma P, Simonetto D, Jalal P, Orman E, Wadei H, St. Hillien S, Saly D, Ufere N, Dageforde L, Regner K, Belcher J, Patidar K, Consortium F. Outcomes of patients with alcohol‐associated hepatitis and acute kidney injury – Results from the HRS Harmony Consortium. Alimentary Pharmacology & Therapeutics 2024, 60: 778-786. PMID: 39010302, PMCID: PMC11349455, DOI: 10.1111/apt.18159.Peer-Reviewed Original ResearchAlcohol-associated hepatitisAcute kidney injuryAcute kidney injury phenotypesHepatorenal syndromeMELD-NaDevelopment of acute kidney injuryCumulative incidence of deathConsecutive adult patientsOutcomes of patientsAlcohol Abuse and Alcoholism (NIAAANon-AH groupRenal replacement therapyPresence of AHAcute tubular necrosisRetrospective cohort studyPredictors of mortalityIncidence of deathAKI stageClinical courseReplacement therapyAdult patientsKidney injuryCumulative incidencePoor prognosisTubular necrosisExploring Novel Adverse Events of Nefecon
Wang J, Zhang Z, Liu X, Shi S, Lv J, Zhang Y, Zhang H. Exploring Novel Adverse Events of Nefecon. Kidney International Reports 2024, 9: 2705-2717. PMID: 39291217, PMCID: PMC11403076, DOI: 10.1016/j.ekir.2024.07.006.Peer-Reviewed Original ResearchAdverse eventsFood and Drug AdministrationFDA Adverse Event Reporting SystemSystem organ classNovel adverse eventsSubgroup analysisDisproportionate analysisFailure type profileUS Food and Drug AdministrationUS FDA Adverse Event Reporting SystemAdverse Event Reporting SystemMedical Dictionary of Regulatory ActivitiesEuropean Medicines AgencyClinical vigilanceEvent Reporting SystemSafety profileCumulative incidencePostmarketing dataIgA nephropathyClinical eventsPositive PTDrug AdministrationRelative riskMedicines AgencyClinical prioritySecond primary non-breast cancers in young breast cancer survivors
Zhang B, Brantley K, Rosenberg S, Kirkner G, Collins L, Ruddy K, Tamimi R, Schapira L, Borges V, Warner E, Come S, Winer E, Bellon J, Partridge A. Second primary non-breast cancers in young breast cancer survivors. Breast Cancer Research And Treatment 2024, 207: 587-597. PMID: 38858235, DOI: 10.1007/s10549-024-07400-z.Peer-Reviewed Original ResearchPrimary non-breast cancerNon-breast cancerSubdistribution hazard ratiosYoung breast cancer survivorsStage 0-III BCBreast cancer survivorsConfidence intervalsGray subdistribution hazard modelRisk factorsMedical record reviewPrimary BCBreast cancerCumulative incidenceBC survivorsCancer survivorsYoung breast cancerSubdistribution hazard modelPrimary tumor characteristicsMedian follow-upRecord reviewType of malignancyGermline geneticsHazard ratioLong-term surveillancePatient factorsSecond Primary Breast Cancer in Young Breast Cancer Survivors
Brantley K, Rosenberg S, Collins L, Ruddy K, Tamimi R, Schapira L, Borges V, Warner E, Come S, Zheng Y, Kirkner G, Snow C, Winer E, Partridge A. Second Primary Breast Cancer in Young Breast Cancer Survivors. JAMA Oncology 2024, 10: 718-725. PMID: 38602683, PMCID: PMC11009864, DOI: 10.1001/jamaoncol.2024.0286.Peer-Reviewed Original ResearchGenetic testingYoung Women's Breast Cancer StudyYoung breast cancer survivorsBreast cancerBreast cancer survivorsYoung BC survivorsPrimary breast cancerGermline genetic testingIII BCMedical record reviewBreast Cancer StudyGermline pathogenic variantsPathogenic variantsBC survivorsTreatment decision-makingCancer survivorsFine-Gray subdistribution hazard modelCumulative incidencePV carriersSubdistribution hazard modelStage 0Patient surveyCharacterize risk factorsUnilateral mastectomyPrimary BCPersonalized risk assessment of new onset depression in long-term cancer survivors.
Taylor M, Westvold S, Long J, Hyslop T, Wang S, Cecchini M, Leapman M, Leeds I, Lustberg M, Spees L, Wheeler S, Gross C, Oeffinger K, Dinan M. Personalized risk assessment of new onset depression in long-term cancer survivors. Journal Of Clinical Oncology 2024, 42: e13798-e13798. DOI: 10.1200/jco.2024.42.16_suppl.e13798.Peer-Reviewed Original ResearchHistory of depressionIncidence of depressionCumulative incidence of depressionRisk of developing depressionLong-term survivorsPredictors of depressionCancer survivorsDisease specific factorsCumulative incidenceNon-HispanicHigher risk of developing depressionRectal cancerLong-term cancer survivorsBreast cancer survivorsCensus tract povertyColon cancerEpisodes of bipolar I disorderPrevalence of depressionMean survival time modelsDiagnosis of depressionReceipt of treatmentAssociated with prior historyHormone receptor statusPatients aged <Adjuvant endocrine therapyHigh-risk features associated with recurrence in stage I lung adenocarcinoma
Fick C, Dunne E, Vanstraelen S, Toumbacaris N, Tan K, Rocco G, Molena D, Huang J, Park B, Rekhtman N, Travis W, Chaft J, Bott M, Rusch V, Adusumilli P, Sihag S, Isbell J, Jones D. High-risk features associated with recurrence in stage I lung adenocarcinoma. Journal Of Thoracic And Cardiovascular Surgery 2024, 169: 436-444.e6. PMID: 38788834, PMCID: PMC11582076, DOI: 10.1016/j.jtcvs.2024.05.009.Peer-Reviewed Original ResearchCumulative incidence of recurrenceStage I lung adenocarcinomaIncidence of recurrenceClinicopathological featuresStage I LUADCumulative incidenceHighest maximum standardized uptake valueMaximum standardized uptake valueRetrospective analysis of patientsHigh risk of recurrenceHigh riskHistory of lung cancerStage I diseaseStandardized uptake valueVisceral pleural invasionHigh-risk featuresHazard of recurrenceAssociated with recurrenceFeatures associated with recurrenceRisk of recurrenceAnalysis of patientsPrognosis of patientsDay of surgeryR0 resectionSublobar resectionReinterventions After CoreValve/Evolut Transcatheter or Surgical Aortic Valve Replacement for Treatment of Severe Aortic Stenosis
Grubb K, Lisko J, O'Hair D, Merhi W, Forrest J, Mahoney P, Van Mieghem N, Windecker S, Yakubov S, Williams M, Chetcuti S, Deeb G, Kleiman N, Althouse A, Reardon M. Reinterventions After CoreValve/Evolut Transcatheter or Surgical Aortic Valve Replacement for Treatment of Severe Aortic Stenosis. JACC Cardiovascular Interventions 2024, 17: 1007-1016. PMID: 38573257, DOI: 10.1016/j.jcin.2024.01.292.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAortic ValveAortic Valve StenosisFemaleHeart Valve ProsthesisHeart Valve Prosthesis ImplantationHumansIncidenceMalePostoperative ComplicationsProsthesis DesignRandomized Controlled Trials as TopicRetreatmentRisk AssessmentRisk FactorsSeverity of Illness IndexTime FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeConceptsSurgical aortic valve replacementTranscatheter aortic valve replacementIncidence of reinterventionAortic valve replacementCumulative incidence of reinterventionValve replacementValve reinterventionCumulative incidenceCoreValve transcatheter aortic valve replacementLow incidence of reinterventionSurgical aortic valve replacement patientsSingle-arm studyFirst-generation CoreValveEvolut R/ProParavalvular regurgitationReinterventionRandomized trialsLow incidenceCoreValvePooled dataTranscatheterIncidenceTreatmentYearsEndocarditisDoes the shape of the copper intrauterine device play a role in expulsion? Results from the ongoing European Active Surveillance Study on LCS12
Boehnke T, Bauerfeind A, Eggebrecht L, Cellier C, Lange J, Heinemann K, Madden T. Does the shape of the copper intrauterine device play a role in expulsion? Results from the ongoing European Active Surveillance Study on LCS12. Contraception 2024, 140: 110444. PMID: 38552821, DOI: 10.1016/j.contraception.2024.110444.Peer-Reviewed Original ResearchConceptsCopper intrauterine deviceEuropean Active Surveillance StudyIntrauterine deviceCopper IUD usersActive surveillance studyNova-TFrameless intrauterine deviceRisk of expulsionIUD usersIntrauterine ballHazard ratioSurveillance studyHeavy menstrual bleedingCox regression analysisIncidence of expulsionHigher risk of expulsionMenstrual bleedingCumulative incidenceCounseling patientsClinical importanceLow riskHigh riskSecondary analysisClinician experienceCliniciansIncidence of non-AIDS defining comorbidities among young adults with perinatally acquired HIV in North America
Haw N, Lesko C, Ng D, Lam J, Lang R, Kitahata M, Crane H, Eron J, Gill M, Horberg M, Karris M, Loutfy M, McGinnis K, Moore R, Althoff K, Agwu A. Incidence of non-AIDS defining comorbidities among young adults with perinatally acquired HIV in North America. AIDS 2024, 38: 1366-1374. PMID: 38507583, PMCID: PMC11211058, DOI: 10.1097/qad.0000000000003892.Peer-Reviewed Original ResearchPerinatally-acquired HIVChronic kidney diseaseMedication useIncidence rateNorth American AIDS Cohort CollaborationElectronic health recordsRoutine HIV careCumulative incidenceResearch and DesignIncidence of diabetes mellitus type 2Young adultsQuasi-Poisson regressionNon-Black femalesDescription of outcomesGlycosylated haemoglobin >Clinical diagnosisHIV careHealth recordsNA-ACCORDBlack adultsIncidence of hypercholesterolemiaDiabetes mellitus type 2Hypertension incidenceCKD incidenceAmerican adultsCardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study)
Green J, Everett B, Ghosh A, Younes N, Krause-Steinrauf H, Barzilay J, Desouza C, Inzucchi S, Pokharel Y, Schade D, Scrymgeour A, Tan M, Utzschneider K, Mudaliar S, Crandall J, McKee M, Behringer-Massera S, Brown-Friday J, Xhori E, Ballentine-Cargill K, Duran S, Estrella H, Gonzalez de la Torre S, Lukin J, Phillips L, Burgess E, Olson D, Rhee M, Wilson P, Raines T, Boers J, Costello J, Maher-Albertelli M, Mungara R, Savoye L, White C, Gullett C, Holloway L, Morehead F, Person S, Sibymon M, Tanukonda S, Adams C, Ross A, Balasubramanyam A, Gaba R, Gonzalez Hattery E, Ideozu A, Jimenez J, Montes G, Wright C, Hollander P, Roe E, Jackson A, Smiley A, Burt P, Estrada L, Chionh K, Ismail-Beigi F, Falck-Ytter C, Sayyed Kassem L, Sood A, Tiktin M, Kulow T, Newman C, Stancil K, Cramer B, Iacoboni J, Kononets M, Sanders C, Tucker L, Werner A, Maxwell A, McPhee G, Patel C, Colosimo L, Krol A, Goland R, Pring J, Alfano L, Kringas P, Hausheer C, Tejada J, Gumpel K, Kirpitch A, Schneier H, AbouAssi H, Chatterjee R, Feinglos M, English Jones J, Khan S, Kimpel J, Zimmer R, Furst M, Satterwhite B, Thacker C, Evans Kreider K, Mariash C, Mather K, Ismail H, Lteif A, Mullen M, Hamilton T, Patel N, Riera G, Jackson M, Pirics V, Aguillar D, Howard D, Hurt S, Bergenstal R, Carlson A, Martens T, Johnson M, Hill R, Hyatt J, Jensen C, Madden M, Martin D, Willis H, Konerza W, Yang S, Kleeberger K, Passi R, Fortmann S, Herson M, Mularski K, Glauber H, Prihoda J, Ash B, Carlson C, Ramey P, Schield E, Torgrimson-Ojerio B, Arnold K, Kauffman B, Panos E, Sahnow S, Bays K, Berame K, Cook J, Ghioni D, Gluth J, Schell K, Criscola J, Friason C, Jones S, Nazarov S, Rassouli N, Puttnam R, Ojoawo B, Nelson R, Curtis M, Hollis B, Sanders-Jones C, Stokes K, El-Haqq Z, Kolli A, Tran T, Wexler D, Larkin M, Meigs J, Chambers B, Dushkin A, Rocchio G, Yepes M, Steiner B, Dulin H, Cayford M, Chu K, DeManbey A, Hillard M, Martin K, Thangthaeng N, Gurry L, Kochis R, Raymond E, Ripley V, Stevens C, Park J, Aroda V, Ghazi A, Magee M, Ressing A, Loveland A, Hamm M, Hurtado M, Kuhn A, Leger J, Manandhar L, Mwicigi F, Sanchez O, Young T, Garg R, Lagari-Libhaber V, Florez H, Valencia W, Marks J, Casula S, Oropesa-Gonzalez L, Hue L, Cuadot A, Nieto-Martinez R, Riccio Veliz A, Gutt M, Kendal Y, Veciana B, Ahmann A, Aby-Daniel D, Joarder F, Morimoto V, Sprague C, Yamashita D, Cady N, Rivera-Eschright N, Kirchhoff P, Morales Gomez B, Adducci J, Goncharova A, Hox S, Petrovitch H, Matwichyna M, Jenkins V, Broadwater L, Ishii R, Bermudez N, Hsia D, Cefalu W, Greenway F, Waguespack C, King E, Fry G, Dragg A, Gildersleeve B, Arceneaux J, Haynes N, Thomassie A, Pavlionis M, Bourgeois B, Hazlett C, Henry R, Boeder S, Pettus J, Diaz E, Garcia-Acosta D, Maggs S, DeLue C, Stallings A, Castro E, Hernandez S, Krakoff J, Curtis J, Killean T, Khalid M, Joshevama E, Diaz E, Martin D, Tsingine K, Karshner T, Albu J, Pi-Sunyer F, Frances S, Maggio C, Ellis E, Bastawrose J, Gong X, Banerji M, August P, Lee M, Lorber D, Brown N, Josephson D, Thomas L, Tsovian M, Cherian A, Jacobson M, Mishko M, Kirkman M, Buse J, Diner J, Dostou J, Machineni S, Young L, Bergamo K, Goley A, Kerr J, Largay J, Guarda S, Cuffee J, Culmer D, Fraser R, Almeida H, Coffer S, Debnam E, Kiker L, Morton S, Josey K, Fuller G, Garvey W, Cherrington A, Dyer D, Lawson M, Griffith O, Agne A, McCullars S, Cohen R, Craig J, Rogge M, Burton K, Kersey K, Wilson C, Lipp S, Vonder Meulen M, Adkins C, Onadeko T, Rasouli N, Baker C, Schroeder E, Razzaghi M, Lyon C, Penaloza R, Underkofler C, Lorch R, Douglass S, Steiner S, Sivitz W, Cline E, Knosp L, McConnell J, Lowe T, Herman W, Pop-Busui R, Martin C, Waltje A, Katona A, Goodhall L, Eggleston R, Kuo S, Bojescu S, Bule S, Kessler N, LaSalle E, Whitley K, Seaquist E, Bantle A, Harindhanavudhi T, Kumar A, Redmon B, Bantle J, Coe M, Mech M, Taddese A, Lesne L, Smith S, Kuechenmeister L, Shivaswamy V, Burbach S, Rodriguez M, Seipel K, Alfred A, Morales A, Eggert J, Lord G, Taylor W, Tillson R, Adolphe A, Burge M, Duran-Valdez E, Martinez J, Bancroft A, Kunkel S, Ali Jamaleddin Ahmad F, Hernandez McGinnis D, Pucchetti B, Scripsick E, Zamorano A, DeFronzo R, Cersosimo E, Abdul-Ghani M, Triplitt C, Juarez D, Mullen M, Garza R, Verastiqui H, Wright K, Puckett C, Raskin P, Rhee C, Abraham S, Jordan L, Sao S, Morton L, Smith O, Osornio Walker L, Schnurr-Breen L, Ayala R, Kreymer R, Sturgess D, Kahn S, Alarcon-Casas Wright L, Boyko E, Tsai E, Trence D, Trikudanathan S, Fattaleh B, Montgomery B, Atkinson K, Kozedub A, Concepcion T, Moak C, Prikhodko N, Rhothisen S, Elasy T, Martin S, Shackelford L, Goidel R, Hinkle N, Lovell C, Myers J, Lipps Hogan J, McGill J, Salam M, Schweiger T, Kissel S, Recklein C, Clifton M, Tamborlane W, Camp A, Gulanski B, Pham K, Alguard M, Gatcomb P, Lessard K, Perez M, Iannone L, Magenheimer E, Montosa A, Cefalu W, Fradkin J, Burch H, Bremer A, Nathan D, Lachin J, Buse J, Kahn S, Larkin M, Tiktin M, Wexler D, Burch H, Bremer A, Lachin J, Bebu I, Butera N, Buys C, Fagan A, Gao Y, Gramzinski M, Hall S, Kazemi E, Legowski E, Liu H, Suratt C, Tripputi M, Arey A, Backman M, Bethepu J, Lund C, Mangat Dhaliwal P, McGee P, Mesimer E, Ngo L, Steffes M, Seegmiller J, Saenger A, Arends V, Gabrielson D, Conner T, Warren S, Day J, Huminik J, Soliman E, Zhang Z, Campbell C, Hu J, Keasler L, Hensley S, Li Y, Herman W, Kuo S, Martin C, Waltje A, Mihalcea R, Min D, Perez-Rosas V, Prosser L, Resnicow K, Ye W, Shao H, Zhang P, Luchsinger J, Sanchez D, Assuras S, Groessl E, Sakha F, Chong H, Hillery N, Abdouch I, Bahtiyar G, Brantley P, Broyles F, Canaris G, Copeland P, Craine J, Fein W, Gliwa A, Hope L, Lee M, Meiners R, Meiners V, O’Neal H, Park J, Sacerdote A, Sledge Jr E, Soni L, Steppel-Reznik J, Turchin A. Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study). Circulation 2024, 149: 993-1003. PMID: 38344820, PMCID: PMC10978227, DOI: 10.1161/circulationaha.123.066604.Peer-Reviewed Original ResearchConceptsType 2 diabetesGlucose-lowering medicationsCardiovascular diseaseMACE-4MACE-3Baseline prevalence of cardiovascular diseasesCardiovascular outcomesPrevalence of cardiovascular diseaseCohort of adultsContemporary cohort of adultsCox proportional hazards modelsEffects of glucose-lowering medicationsLow cardiovascular riskProportional hazards modelType 2 diabetes durationRisk of cardiovascular eventsPrespecified outcomesHazards modelCardiovascular riskInvestigated cardiovascular outcomesLow riskLiraglutide-treated groupStatistically significant differenceHeart failureCumulative incidence
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply